Inclusion Criteria:

   - Biopsy-confirmed relapsed, refractory, or progressive NHL or HL (Refer to Section
   3.2.1 for excluded subtypes)

   - At least 3 sites of disease

      1. One for diagnosis (lymph node or bone marrow biopsy)

      2. One palpable for treatment

      3. One measurable radiographically

   - > 60 days after RIC allogeneic transplant for lymphoma

   - 18 years of age or older

   - Mixed (5-95%) or complete (>95%) chimerism

   - Eastern Oncology Cooperative Group (ECOG) performance status ≤ 2

   - ANC >1000/mm3, platelets >50,000/mm3

   - Total bilirubin ≤ 2.5 mg/dL, AST and ALT < 3 times upper limit of normal

   - Serum creatinine ≤ 3 mg/dL

   - No chemotherapy, RT, DLI or biologic therapy for lymphoma at least 4 weeks prior to
   scheduled treatment

   - Minimal immunosuppression (defined as monotherapy with ≤ 10 mg prednisone daily, ≤ 200
   mg cyclosporine daily, or ≤ 2 mg tacrolimus daily) at least 2 weeks prior to scheduled
   treatment

Exclusion Criteria:

   - HIV associated lymphoma

   - Acute GVHD at time of enrollment (history of treated and resolved GVHD is permitted)

   - Active infection within 14 days prior to scheduled treatment

   - Active Cytomegalovirus (CMV) disease at the time of enrollment

   - Pre-existing autoimmune or antibody mediated disease (including systemic lupus
   erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, and
   autoimmune thrombocytopenia)

   - Pregnant